• DiaSorin’s third-quarter 2026 adjusted net income rose 6% year over year to EUR 53.6 million, while revenue climbed 10% to EUR 308 million.
• Nine-month adjusted net income fell 10% year over year to EUR 159 million, mainly due to higher net financial expenses.
• Third-quarter adjusted EBITDA jumped 16% year over year to EUR 103 million, with an adjusted margin of 33%.
• The LIAISON PLEX Gastrointestinal Flex test secured CE certification under IVDR, expanding the customizable syndromic diagnostics offering in Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaSorin S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 0957-109-2026_TELEBORSA.pdf), on November 12, 2026, and is solely responsible for the information contained therein.